Position history for FARALLON CAPITAL MANAGEMENT LLC's holdings in CRINETICS PHARMACEUTICALS IN
FARALLON CAPITAL MANAGEMENT LLC holds 8.3M shares of CRNX (CRINETICS PHARMACEUTICALS IN), worth $302.8M as of 2026-Q1. The position was increased (+20.3% shares). CRNX represents 1.7% of FARALLON CAPITAL MANAGEMENT LLC's portfolio.
Current Value
$302.8M
Current Shares
8.3M
Total Value Change
+$280.6M
Total Shares Change
+7.8M
Other major holders of CRNX: BNP PARIBAS FINANCIAL MARKETS, FMR LLC, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
Increased |
| 8.3M |
+20.3% |
| $302.8M |
| 1.7% |
| $40.12 |
58 |
| 2025-Q4 | Increased | 6.9M | +20.2% | $322.7M | 1.5% | $47.39 | 58 |
| 2025-Q3 | Increased | 5.8M | +24.2% | $240.3M | 1.0% | $43.51 | 53 |
| 2025-Q2 | Increased | 4.6M | +0.9% | $133.6M | 0.6% | $29.96 | 43 |
| 2025-Q1 | Increased | 4.6M | +13.0% | $154.5M | 0.9% | $34.73 | 48 |
| 2024-Q4 | Increased | 4.1M | +250.7% | $208.4M | 1.1% | $50.67 | 78 |
| 2024-Q3 | Increased | 1.2M | +133.8% | $59.4M | 0.3% | $50.75 | 57 |
| 2024-Q2 | Increased | 497,000 | +9840.0% | $22.3M | 0.1% | $44.79 | 55 |